New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
07:59 EDTCLDXCelldex reiterated as a Focus Pick at Roth Capital
Roth Capital reiterated Celldex as its Focus Pick citing its broad pipeline and the potential for accelerated approval for either ORR or PFS. Shares are Buy rated with a $16 price target.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
08:07 EDTCLDXCelldex appoints Richard Wright as Chief Commercial Officer
Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.
June 29, 2015
08:26 EDTCLDXCelldex announces independent DSMB recommends continuation of Rintega study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use